Lyell Immunopharma (LYEL) Change in Account Payables (2020 - 2026)

Lyell Immunopharma has reported Change in Account Payables for 7 years, with the latest figure at $2.4 million in Q1 2026.

• Quarterly Change in Account Payables rose 244.07% year-over-year to $2.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 million (up 135.56% YoY) and the FY2025 annual result came in at -$2.3 million, up 27.67% from the prior year.
• Change in Account Payables advanced to $2.4 million in Q1 2026 per LYEL's latest filing, from $325000.0 in the prior quarter.
• Over five years, Change in Account Payables peaked at $2.9 million in Q1 2022 and troughed at -$2.0 million in Q4 2024.
• A 5-year average of -$62294.1 and a median of -$231000.0 in 2025 frame the typical range for Change in Account Payables.
• The sharpest annual moves came in 2022 and 2023: Change in Account Payables soared 363.25% in 2022, then tumbled 6230.43% in 2023.
• Over 5 years, Change in Account Payables stood at -$526000.0 in 2022, then jumped by 180.8% to $425000.0 in 2023, then slumped by 579.06% to -$2.0 million in 2024, then soared by 115.96% to $325000.0 in 2025, then soared by 633.23% to $2.4 million in 2026.
• According to Business Quant data, Change in Account Payables over the past three periods registered $2.4 million, $325000.0, and -$779000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.